An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced participation in a fireside chat at the Cantor Virtual Global Healthcare Conference on September 27, 2021, at 8:40 a.m. ET. A live webcast will be accessible on their website, with an audio archive available for 30 days post-event. KalVista focuses on developing small molecule protease inhibitors for unmet medical needs, with significant products like KVD900 for hereditary angioedema (HAE) and KVD001 for diabetic macular edema (DME) in clinical trials.
Positive
None.
Negative
None.
CAMBRIDGE, Mass. & SALISBURY, United Kingdom--(BUSINESS WIRE)--
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m. ET.
A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be available on KalVista’s website for 30 days following the presentation.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 2 KOMPLETE clinical trial, and to obtain regulatory approvals for KVD900, KVD824 and other candidates in development, the ability of KVD900, KVD824 and other candidates in development to treat HAE or DME, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2021, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
When is KalVista's presentation at the Cantor Virtual Global Healthcare Conference?
KalVista Pharmaceuticals will present at the Cantor Virtual Global Healthcare Conference on September 27, 2021, at 8:40 a.m. ET.
Where can I watch the KalVista presentation?
The KalVista presentation will be available as a live webcast on their website, with an audio archive for 30 days after the conference.
What is KalVista Pharmaceuticals focused on?
KalVista Pharmaceuticals focuses on the discovery and development of small molecule protease inhibitors for diseases, including hereditary angioedema and diabetic macular edema.
What are the key products in KalVista's pipeline?
Key products include KVD900, an oral therapy for acute hereditary angioedema attacks, and KVD001, an intravitreal injection for diabetic macular edema.
What clinical trials are KalVista conducting?
KalVista is conducting the Phase 2 KOMPLETE clinical trial for KVD824 and has completed a Phase 2 trial for KVD001.
